220 related articles for article (PubMed ID: 15482167)
21. Thymalfasin in the treatment of hepatitis B and C.
Ciancio A; Rizzetto M
Ann N Y Acad Sci; 2010 Apr; 1194():141-6. PubMed ID: 20536462
[TBL] [Abstract][Full Text] [Related]
22. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.
Moscarella S; Buzzelli G; Romanelli RG; Monti M; Giannini C; Careccia G; Marrocchi EM; Zignego AL
Liver; 1998 Oct; 18(5):366-9. PubMed ID: 9831367
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach.
Naylor PH; Mutchnick MG
J Viral Hepat; 2018 Jan; 25(1):4-9. PubMed ID: 29052304
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
25. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey.
Saruc M; Yuceyar H; Kucukmetin N; Demir MA; Kandiloglu AR
Hepatogastroenterology; 2002; 49(45):798-802. PubMed ID: 12063993
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - first announcement of the protocol.
Qiu SJ; Zhou ZG; Shen F; Li AJ; Chen MS; Ying MG; Chen Z; Zhang YX; Sun HC; Fan J
Expert Opin Biol Ther; 2015; 15 Suppl 1():S133-7. PubMed ID: 26094695
[TBL] [Abstract][Full Text] [Related]
27. Management of viral hepatitis B.
Pramoolsinsup C
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
[TBL] [Abstract][Full Text] [Related]
28. Thymosin alpha in the treatment of chronic hepatitis B: an uncontrolled open-label trial.
Amarapurkar D; Das HS
Indian J Gastroenterol; 2002; 21(2):59-61. PubMed ID: 11990327
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.
Saruc M; Ozden N; Turkel N; Ayhan S; Hock LM; Tuzcuoglu I; Yuceyar H
J Pharm Sci; 2003 Jul; 92(7):1386-95. PubMed ID: 12820143
[TBL] [Abstract][Full Text] [Related]
30. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.
Andreone P; Gramenzi A; Cursaro C; Felline F; Loggi E; D'Errico A; Spinosa M; Lorenzini S; Biselli M; Bernardi M
J Viral Hepat; 2004 Jan; 11(1):69-73. PubMed ID: 14738560
[TBL] [Abstract][Full Text] [Related]
31. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.
Lim SG; Wai CT; Lee YM; Dan YY; Sutedja DS; Wee A; Suresh S; Wu YJ; Machin D; Lim CC; Fock KM; Koay E; Bowden S; Locarnini S; Ishaque SM
Antivir Ther; 2006; 11(2):245-53. PubMed ID: 16640105
[TBL] [Abstract][Full Text] [Related]
32. [Antiviral therapy of chronic hepatitis B patients resistant to lamivudine].
Cui SN; Wang MM
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Dec; 19(4):395-7. PubMed ID: 16416004
[TBL] [Abstract][Full Text] [Related]
33. Thymosin alpha-1 treatment in chronic hepatitis B.
Wu X; Jia J; You H
Expert Opin Biol Ther; 2015; 15 Suppl 1():S129-32. PubMed ID: 25640173
[TBL] [Abstract][Full Text] [Related]
34. [Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis].
Mao HY; Shi TD
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):29-33. PubMed ID: 21272455
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
Andreone P; Cursaro C; Gramenzi A; Zavagliz C; Rezakovic I; Altomare E; Severini R; Franzone JS; Albano O; Ideo G; Bernardi M; Gasbarrini G
Hepatology; 1996 Oct; 24(4):774-7. PubMed ID: 8855175
[TBL] [Abstract][Full Text] [Related]
36. [B domain mutations in the polymerase gene of hepatitis B virus during combination therapy with thymosin alpha1 and famciclovir in Chinese asymptomatic HBV carriers].
Hou J; Wang Z; Sun J
Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):574-6. PubMed ID: 11798819
[TBL] [Abstract][Full Text] [Related]
37. Thymosin alpha-1.
Ancell CD; Phipps J; Young L
Am J Health Syst Pharm; 2001 May; 58(10):879-85; quiz 886-8. PubMed ID: 11381492
[TBL] [Abstract][Full Text] [Related]
38. Thymosin in the treatment of HBeAg-negative chronic hepatitis B.
Saruc M; Ozden N; Yuceyar H
Med Sci Monit; 2003 Aug; 9(8):RA198-202. PubMed ID: 12942046
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma.
Rasi G; Pierimarchi P; Sinibaldi Vallebona P; Colella F; Garaci E
Int Immunopharmacol; 2003 Aug; 3(8):1169-76. PubMed ID: 12860172
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.
Chen JF; Chen SR; Lei ZY; Cao HJ; Zhang SQ; Weng WZ; Xiong J; Lin DN; Zhang J; Zheng YB; Gao ZL; Lin BL
Hepatol Int; 2022 Aug; 16(4):775-788. PubMed ID: 35616850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
